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Introduction
Premature coronary artery disease (CAD) patients are
a special subgroup among atherosclerotic patients.
Premature presentation implies a rapidly progressive
disease course. Moreover, the impact of premature
myocardial infarction (MI) or CAD on the young pa-
tient and his/her family is particularly devastating.
Fortunately, the incidence of MI and symptomatic
CAD in young adults is low; most studies show that
only about 3% of all CAD cases occur under the age
of 40.1,2
The fact that clinically manifest CAD in the young
adult is relatively uncommon implies that these patients
are atypical of the general population.3–8 Cigarette
smoking has been shown to be the single factor most
strongly associated with CAD in young adults.9 Kannel
et al found that in patients included in the Framingham
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Heart Study, the relative risk for CAD was about 
3 times higher in smokers aged 35–44 compared to
nonsmokers in the same age group.9,10 Diabetes and
hyperlipidemia are also important associated risk fac-
tors in premature CAD patients. Family history of CAD
is another known risk factor and probably represents a
combination of multiple risk factors.
Drug-eluting stenting (DES) has been shown to
have a lower restenotic rate in comparison with bare-
metal stenting.11,12 Recently, several clinical trials and
registries have proven the efficacy of DES in high-
risk subsets such as diabetes, small vessels or long
lesions.13–15 However, few studies have investigated
the efficacy and safety of DES for premature CAD
patients, who are usually associated with multiple ath-
erosclerotic risk factors. We conducted this retrospec-
tive study and investigated the short-term results of
DES in premature CAD patients with diverse and
multiple risk factors.
Methods
Study population
Between February 2004 and October 2005, premature
CAD patients, defined as those younger than 50 years
of age, who were treated with DES in Taichung
Veterans General Hospital (Taichung, Taiwan) were
all retrospectively enrolled. Their clinical characteristics,
clinical outcome and angiographic follow-up results
were analyzed. Angiographic follow-up was at the dis-
cretion of the interventional cardiologists in charge.
The clinical follow-up was retrospectively counted up
to May 31, 2006.
Definition of demographic data and
conventional atherosclerotic risk factors
Acute coronary syndrome (ACS) included ST elevation
or non-ST elevation MI with cardiac enzyme elevation
or unstable angina with crescendo chest pain, and
ischemic electrocardiographic changes but no cardiac
enzyme elevation. Hypertension was defined as systolic
blood pressure over 140mmHg or diastolic blood pres-
sure over 90 mmHg after multiple measurements in
the sitting position at rest or patients already on anti-
hypertensive medication. Diabetes mellitus was defined
as fasting blood sugar over 126 mg/dL on 2 occasions
or patients already on oral hypoglycemic agents or
insulin shot. Hyperlipidemia was defined as total cho-
lesterol over 200 mg/dL or low-density lipoprotein
cholesterol (LDL-C) over 130 mg/dL or patients
already on HMG-CoA reductase inhibitor treatment.
Family history of premature CAD was defined as CAD
history in a first-degree male relative before the age of
55 or female before the age of 65.
Percutaneous coronary intervention
Patients received 325 mg of aspirin and a 300-mg oral
dose of clopidogrel before or immediately after the
procedure. Dual antiplatelet agents were maintained for
at least 3 months in sirolimus-eluting stenting (SES)
and for 6 months in paclitaxel-eluting stenting (PES).
The use of either PES or SES was dependent upon
mutual agreement between the patient and the inter-
ventional cardiologist in charge. Target vessel revas-
cularization (TVR) was considered to be driven by
ischemia if the stenosis of the target vessel was at least
50% of the luminal diameter on the basis of a quanti-
tative analysis, with either electrocardiographic changes
while the patient was at rest or a functional study indi-
cating ischemia in the distribution of the target vessel,
or if there was stenosis of at least 70% in conjunction
with recurrent symptoms alone. Target lesion revascu-
larization (TLR) was defined as repeat revascularization
for ischemia owing to stenosis of at least 50% of the
luminal diameter anywhere within the stent or within
the 5-mm borders proximal or distal to the stent. Target
vessel failure was defined as death, MI, or ischemia-
driven TVR. If an adverse event could not conclusively
be attributed to a non-target vessel, the event was
considered a target vessel failure.
Definition of angiographic parameters
The complete angiogram record was reviewed and
angiographic measurements were made on a dedicated
workstation with software for quantitative analysis of
angiograms (QCA) (Philips Inturis Suite, R2.2). The
classification of coronary lesion types was made based
on the American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines. Binary
restenosis was defined as stenosis of at least 50%
diameter of the luminal diameter of previously treated
lesions.
Definition of stent thrombosis
Stent thrombosis was defined as an ACS with angio-
graphic documentation of either vessel occlusion or
thrombus within or adjacent to a previously success-
fully stented vessel or, in the absence of angiographic
confirmation, either acute MI in the distribution of
the treated vessel or death from cardiac causes up to
the end of the defined study period.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation and categorical data as percentages.
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Categorical variables were compared using the χ2 test
with or without Yate’s correction as indicated. SPSS
version 12.1 (SPSS Inc., Chicago, IL, USA) was used
for all calculations. A 2-tailed p value less than 0.05
was considered statistically significant.
Results
Baseline demographic data and conventional
atherosclerotic risk factors
A total of 26 patients (M/F: 23/3) were enrolled, with
a mean age of 44±6 years (median age, 45 years; range,
24–50 years). Conventional atherosclerotic risk factors
were prevalent in this study group, including diabetes
mellitus (35%), hypertension (35%), hyperlipidemia
(54%) and smoking (73%) (Table 1). The mean number
of atherosclerotic risk factors was 3 ± 2. In particular,
there was 1 homozygous and 1 heterozygous familial
hypercholesterolemia patient in our study. The homo-
zygous patient was a 24-year-old woman who presented
with baseline total cholesterol 520 mg/dL, tendon
xanthomas, left main and triple-vessel coronary disease
and carotid atherosclerosis. The heterozygous patient
was a 34-year-old man with baseline total cholesterol
of 400 mg/dL and triple-vessel coronary disease.
Baseline angiographic data of premature CAD
patients treated with DES
There were 40 target lesions in 34 target vessels.
Among the 40 lesions, 25 (62.5%) were type C lesions
and 24 (60%) had reference vessel diameter <3mm. The
mean lesion length was 23.1 ± 5.2 mm. Forty DES (39
PES, 1 SES) were implanted, with a median stent diam-
eter of 3 mm and median length of 24 mm (Table 2).
Follow-up results of premature CAD patients
treated with DES
The clinical follow-up was counted up to May 2006
with a mean follow-up duration of 540 ± 168 days.
Table 1. Baseline clinical data of 26 premature coronary artery
disease patients treated with drug-eluting stents*
Age (yr) 44 ± 6 (range, 24–50)
Male 23 (88)
DM 9 (35)
HT 9 (35)
Hyperlipidemia 14 (54)
Smoking 19 (73)
Family history 5 (19)
Atherosclerotic risk factor per patient 3 ± 2
Prior MI 5 (19)
Clinical diagnosis
AMI 9 (35)
UA 7 (27)
Angina pectoris 10 (38)
LVEF (n = 19) 45 ± 13
Special condition
Homozygous FH 1
Heterozygous FH 1
*Data presented as mean± standard deviation or n (%). DM = diabetes mellitus;
HT = hypertension; MI = myocardial infarction; AMI = acute ST elevation or
non-ST elevation MI; UA = unstable angina; LVEF = left ventricular ejection
fraction; FH = familial hypercholesterolemia.
Table 2. Baseline angiographic data of premature coronary
artery disease patients treated with drug-eluting stents (DES)
Target vessel (n = 34)
LAD 17 (50.0%)
LCX 7 (20.6%)
RCA 9 (26.4%)
LM 1 (3.0%)
Target lesion type (n = 40)
A 1 (2.5%)
B 14 (35.0%)
C 25 (62.5%)
Reference vessel diameter (n = 40) 2.96 ± 0.34 mm
< 3.0 mm 24 (60%)
≥ 3.0 mm 16 (40%)
Lesion length (n = 40) 23.1 ± 5.2 mm
Minimal vessel diameter (n = 40) 0.3 ± 0.2 mm
Stenosis (n = 40) 91.0 ± 7.6% of 
luminal diameter
Median stent diameter 3 mm
Median stent length 24 mm
Stent per patient
1 14 (54%)
2 10 (38%)
3 2 (8%)
Type of DES (PES/SES) 39/1
Final reference vessel diameter 3.1 ± 0.4 mm
Final minimal luminal diameter 3.1 ± 0.4 mm
Final stenosis 2% of diameter
LAD = left anterior descending artery; LCX = left circumflex artery; RCA = right
coronary artery; LM = left main coronary artery; PES = paclitaxel-eluting stent;
SES = sirolimus-eluting stent.
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Eleven (42%) patients had a second angiogram in the
follow-up period (200 ± 98 days after DES) and none
of them had binary restenosis (Table 3). Moreover,
no patients had TLR in the clinical follow-up period.
However, 2 patients (5.9% of intervened vessels) had
TVR (non-target lesion) during follow-up. One was 
a 44-year-old man who had a patent PES site over the
proximal obtuse marginal branch on follow-up angio-
gram but restenosis of the far-distal obtuse marginal
ballooning site (beyond the stented segment). The
other was a 42-year-old man, who received PES at 
the proximal left anterior descending artery (LAD).
On follow-up, he had a patent LAD-proximal stented
site, but a previously untreated LAD-middle lesion be-
came significant and intervention was subsequently per-
formed with balloon angioplasty. No patients developed
stent thrombosis or recurrent acute MI in the clinical
follow-up period. Regarding risk factor modification,
the 14 patients who met the criteria for hypercholes-
terolemia (total cholesterol > 200 mg/dL or LDL-C >
130 mg/dL) were all put on HMG-CoA reductase
inhibitor treatment during the clinical follow-up pe-
riod. Forty-two percent of the original cigarette smok-
ers quit smoking after index percutaneous coronary
intervention (PCI).
Comparison of premature CAD patients with
or without ACS who were treated with DES
Sixteen (62%) of the study patients were admitted due
to ACS, while 10 (38%) were admitted due to stable
angina pectoris. There was no difference in TLR, stent
thrombosis or binary restenosis between the ACS 
and non-ACS groups. Two patients in the ACS group
had non-target lesion TVR (p = 0.684 vs. non-ACS)
(Table 4).
Discussion
Premature CAD demands special clinical attention
because of its devastating impact on patients and their
families.16 DES is gaining popularity among cardiolo-
gists because of its effectiveness in reducing the resteno-
sis rate.11,12 However, concerns about the increased late
or very late stent thrombosis rate in DES have recently
arisen.17,18 Though several trials and registries have
proven the efficacy of DES in the general population,
very few studies have focused on DES application in
premature CAD groups. In our retrospective study, we
showed that DES was a reliable treatment for a prema-
ture CAD group with complex lesions and diverse and
multiple atherosclerotic risk factors.
Our study included 2 rare premature CAD cases
with familial hypercholesterolemia. One was a homozy-
gous 24-year-old woman who presented with baseline
total cholesterol of 520 mg/dL, tendon xanthomas, left
main and triple-vessel coronary disease and carotid
artery stenosis. She was treated with both HMG-CoA
reductase inhibitor and plasma LDL apheresis.19 SES
was implanted in the left main ostium and a PES in
the right coronary artery. However, no skin biopsy was
done to confirm the diagnosis by measuring LDL
receptor activity in the cultured skin fibroblasts of this
patient.20 Another limitation is that there was no follow-
up coronary angiogram in this case. The other patient
was a heterozygous 34-year-old man with baseline
total cholesterol of 400 mg/dL, ischemic resting
electrocardiogram and strong positive treadmill exer-
cise test results. Coronary angiogram showed triple-
vessel coronary disease, and he was treated with a total
of 5 PES in 2 PCI sessions. A radionuclide exercise
myocardial perfusion scan was performed 5 months later
that disclosed negative ischemic response on electrocar-
diography and scan, indicating good therapeutic results.
The study was based on a retrospective analysis of
a single center’s catheterization databank and thus lim-
ited by a small sample size. The clinical implications of
Table 3. Follow-up results of premature coronary artery disease
patients treated with drug-eluting stents
Clinical outcome (patient number = 26; vessel number = 34; 
lesion number = 40)
Mean follow-up days 540 ± 168
Death from cardiac cause (%) 0
Myocardial infarction (%) 0
Stent thrombosis (%) 0
Target lesion revascularization (n = 40) 0
Target vessel (non-target lesion) 2 (5.9%)
revascularization (n = 34)
Target vessel failure (n = 34) 2 (5.9%)
Angiographic follow-up (patient number = 11; 
lesion number = 18)
Binary restenosis 0
Follow-up duration (d) 200 ± 98
Table 4. Comparison of premature coronary artery disease
patients with or without acute coronary syndrome (ACS) who
were treated with drug-eluting stents
ACS Non-ACS 
p
(n = 16) (n = 10)
TLR 0 0 1.000
TVR 2 0 0.684
Stent thrombosis 0 0 1.000
Binary restenosis* 0 0 1.000
*Eleven patients underwent angiography during follow-up. TLR = target lesion
revascularization; TVR = target vessel revascularization.
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our study are also limited by the DES brand selected
(98% PES) as well as gender bias (88% male). Another
limitation is that only 42% of the studied patients had
a second coronary angiogram during the follow-up
period. Moreover, 35% of studied patients presented
with acute MI. According to the literature, young-age
acute MI is associated with more thrombus and less
plaque and thus an inherent lower restenotic rate.21
Another shortcoming of this study was the lack of an
older-age control group that received DES treatment
in the same study time frame.
The mean number of atherosclerotic risk factors
was 3 ± 2 in our study, and 63% of the treated lesions
were ACC/AHA class C. Though most of the treated
lesions were complex and the clinical scenarios were
high risk for restenosis, our short-term follow-up results
disclosed only 2 target vessel failures (5.9%). The
results are compatible with most published clinical tri-
als in high-risk subsets.14,15 Our study results indicate
that young age or premature CAD is not a limitation
to DES-based PCI in current practice. Moreover,
recent results from the COURAGE trial by Boden et al
emphasized the importance of risk factor modification
for the treatment of stable angina pectoris.22 Our study
results on young premature CAD subjects again proved
this notion as all our patients with hypercholesterolemia
were put on HMG-CoA reductase inhibitor treatment
during the clinical follow-up period.
In conclusion, based on our single-center experi-
ence, DES was a reliable treatment with a very low TLR
(0%) for a premature CAD group with complex lesions
and diverse and multiple atherosclerotic risk factors.
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